- Home
- OKYO vs NSPR Comparison
OKYO vs NSPR Comparison
Compare OKYO & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | NSPR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 67.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | NSPR |
|---|---|---|
| Price | $2.17 | $1.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 252.8K | 42.0K |
| Earning Date | 07-18-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $0.90 | $1.51 |
| 52 Week High | $3.35 | $3.80 |
Technical Indicators
Market Signals| Indicator | OKYO | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 42.40 |
| Support Level | $1.97 | $1.53 |
| Resistance Level | $3.20 | $1.74 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 17.80 | 33.72 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.